We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · April 20, 2021

Second-Line Metformin Combination Therapies and HbA1c, Body Weight, and Glucose-Lowering Treatment Intensification

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Associations Between Second-Line Glucose-Lowering Combination Therapies With Metformin and HbA1c, Body Weight, Quality of Life, Hypoglycaemic Events, and Glucose-Lowering Treatment Intensification: The DISCOVER Study
Diabetes Obes Metab 2021 Apr 14;[EPub Ahead of Print], K Khunti, B Charbonnel, A Cooper, MB Gomes, L Ji, P Leigh, A Nicolucci, W Rathmann, MV Shestakova, A Siddiqui, F Tang, H Watada, H Chen,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading